|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0030297,
umls-concept:C0185117,
umls-concept:C0245662,
umls-concept:C0253023,
umls-concept:C0439662,
umls-concept:C0870509,
umls-concept:C0940731,
umls-concept:C1539477,
umls-concept:C1547898,
umls-concept:C1705955,
umls-concept:C2911684
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2002-8-13
|
|
pubmed:abstractText |
Fas (CD95/APO-1) and Fas ligand (FasL) play key roles in immunologic homeostasis and immune privilege and may regulate normal cell turnover. Earlier studies had suggested that FasL-positive pancreatic carcinoma cell lines can induce apoptosis in T cells, thereby evading host immune surveillance. In the current study the authors have characterized the expression of Fas and FasL in the normal pancreas and in pancreatic neoplasia.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
94
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2552-60
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:12173320-Adult,
pubmed-meshheading:12173320-Aged,
pubmed-meshheading:12173320-Aged, 80 and over,
pubmed-meshheading:12173320-Antigens, CD95,
pubmed-meshheading:12173320-Carcinoma, Ductal, Breast,
pubmed-meshheading:12173320-Chronic Disease,
pubmed-meshheading:12173320-Fas Ligand Protein,
pubmed-meshheading:12173320-Female,
pubmed-meshheading:12173320-Humans,
pubmed-meshheading:12173320-Immunoblotting,
pubmed-meshheading:12173320-Immunohistochemistry,
pubmed-meshheading:12173320-Male,
pubmed-meshheading:12173320-Membrane Glycoproteins,
pubmed-meshheading:12173320-Middle Aged,
pubmed-meshheading:12173320-Pancreas,
pubmed-meshheading:12173320-Pancreatic Ducts,
pubmed-meshheading:12173320-Pancreatic Neoplasms,
pubmed-meshheading:12173320-Pancreatitis,
pubmed-meshheading:12173320-Survival Rate
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors. Implications for immune privilege and immune escape.
|
|
pubmed:affiliation |
Laboratory of Biologic Cancer Therapy, Division of Surgical Oncology, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
